Parabilis Medicines, Inc. 4

RA Capital Management, L.P. (through its healthcare and Nexus funds) bought 241,593 shares of Parabilis Medicines, Inc. voting common stock in the open market on July 20–22, 2026 at prices around $27–30 per share.

On July 20–22, 2026, RA Capital Management, L.P., on behalf of its affiliated funds, reported a series of open‑market purchases of Parabilis Medicines, Inc. voting common stock, accumulating a total of 241,593 shares at weighted‑average prices between approximately $27.13 and $30.00 per share. These trades increased the funds’ indirect beneficial ownership from 26,383,526 shares to 26,529,686 shares, with shares held directly by RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., while RA Capital Management GP, LLC and managing members Dr. Peter Kolchinsky and Rajeev Shah, as well as the Adviser itself, each disclaim beneficial ownership beyond their pecuniary interest. The transactions, executed in multiple tranches with specified price ranges, represent a sizable incremental purchase by a concentrated healthcare investor whose partner, Dr. Jake Simson, sits on Parabilis’s board of directors.

Filing Facts

CIK

1657677

Ticker

PBLS

Form

4

Source Type

fda

Accession

0001231919-26-000779

Alert Tier

7

ATTN Analysis